Add to a list

Inactive Instrument

PCAS Stock

PCA

FR0000053514

Pharmaceuticals

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrows Top Investments!

SEIZE THE OFFER!

09/02/24	Orapi: takeover bid reopens on February 12
02/02/24	Orapi: 3.15 million shares tendered to the takeover bid
22/12/23	Orapi: takeover bid opens on December 27
18/12/23	PCAS: 200 ME capital increase
03/11/23	PCAS: OPAS to start this Friday
24/10/23	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
16/10/23	Progyny, Inc. : Want to have a baby?
07/09/23	PCAS: Seqens launches minority share offer
06/09/23	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/07/23	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
01/06/23	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
25/05/23	PCAS: sale of Canadian subsidiary confirmed
25/05/23	PCAS to Divest Canadian Arm to Japan's DIC	MT

24/10/23	PCAS: Net Sales as of September 30, 2023	GL
06/09/23	PCAS: RESULTS AS OF JUNE 30, 2023	GL
27/07/23	Pcas: Net sales as of June 30, 2023	GL
25/05/23	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
02/05/23	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

09/02/24	Orapi : l'OPA réouvre le 12 février
02/02/24	Orapi : 3,15 millions d'actions apportées à l'OPA
05/01/24	Progyny, Inc.: ¿Quieres tener un bebé?
22/12/23	Orapi : l'OPA démarre le 27 décembre
18/12/23	PCAS : augmentation de capital de 200 ME

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	03/05/2025
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	01/03/1999

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	01/03/2014
Janine Cossy BRD	Director/Board Member	-	-

PCAS Stock

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news : PCAS

Press Releases: PCAS

News in other languages: PCAS

Managers and Directors: PCAS

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	125M
ELI LILLY AND COMPANY	+2.16%	+3.17%	+43.57%	+160.28%	1,035B
JOHNSON & JOHNSON	-0.07%	+4.45%	+53.50%	+48.95%	574B
ABBVIE INC.	-0.08%	-0.08%	+17.37%	+62.66%	397B
ROCHE HOLDING AG	+0.38%	+0.77%	+21.19%	+15.95%	324B
ASTRAZENECA PLC	+0.24%	-1.95%	+23.19%	+14.86%	281B
NOVARTIS AG	+0.76%	+3.56%	+24.58%	+34.50%	278B
NOVO NORDISK A/S	+0.34%	+3.64%	-45.70%	-48.46%	193B
AMGEN INC.	+4.84%	+2.45%	+21.33%	+61.85%	191B
GILEAD SCIENCES, INC.	+3.61%	-2.56%	+15.16%	+61.12%	156B
Average	+0.58%	+1.68%	+19.36%	+45.75%	381.1B
Weighted average by Cap.	+0.26%	+2.39%	+29.32%	+72.85%